Breaking News
September 25, 2018 - Antibiotics best paediatric treatment for children’s chronic wet cough
September 25, 2018 - Looking beyond opioids: Stanford pain psychologist briefs Congress
September 25, 2018 - Organs actively fighting back against autoimmune diseases, finds study
September 25, 2018 - Lancaster professor aims to understand how genes affect smoking cessation
September 25, 2018 - Human-oriented perspective needed to better understand Parkinson’s disease
September 25, 2018 - Physical activity may have beneficial effects for people with rare Alzheimer’s disease
September 25, 2018 - FDA Updates on Valsartan Recalls
September 25, 2018 - 3-D-printed tracheal splints used in groundbreaking pediatric surgery
September 25, 2018 - Who is the designated driver, or proxy, for your health decisions?
September 25, 2018 - New chemo-optogenetic method enables multi-directional activity control of cellular processes
September 25, 2018 - Study explores link between genetic predisposition to Alzheimer’s and cardiometabolic risk factors
September 25, 2018 - NeoTract presents new clinical data from studies of UroLift System for patients with BPH
September 25, 2018 - Statins Improve Long-Term Survival After AAA Repair
September 25, 2018 - Novel brain network linked to chronic pain in Parkinson’s disease
September 25, 2018 - Researchers reassess negative pressure wound therapy as its benefit and harm remain unclear
September 25, 2018 - Older adults with ‘fall plan of care’ less likely to suffer fall-related hospitalizations
September 25, 2018 - FDA lifts partial clinical hold that paused enrollment of new patients in tazemetosta clinical trials
September 25, 2018 - IME Medical Electrospinning establishes state-of-the-art manufacturing lab facilities
September 25, 2018 - Phase 1 and 2 clinical trials of entrectinib drug in ROS1-positive NSCLC show promising results
September 25, 2018 - How to Protect Your Eyesight
September 25, 2018 - Novel approach allows researchers to define how cells in the retina respond to diabetes
September 25, 2018 - Columbia University announces winners of 2018 Louisa Gross Horwitz Prize
September 25, 2018 - Clinical trial investigators found non-compliant with requirement to report results on EU register
September 25, 2018 - Study analyzes quality of protein supplements in function of source, treatment and storage
September 25, 2018 - FDA grants Orphan Drug Designation to Myelo001 for treatment of Acute Radiation Syndrome
September 25, 2018 - U.S. Alzheimer’s Cases to Nearly Triple by 2060
September 25, 2018 - Improving cell replacement therapy for Parkinson’s disease
September 25, 2018 - Genervon reports new findings that drug candidate GM6 attenuates Alzheimer’s disease in mice model
September 25, 2018 - FDA approves new 5 mm diameter drug-eluting stent from Cook Medical
September 25, 2018 - New $17.8 million grant ensures USC at forefront of research on tobacco-related health risks
September 25, 2018 - Researchers analyze response to combination immunotherapy for patients with rare skin cancer
September 25, 2018 - Study sheds light on how brain protein may be involved neurodevelopmental disorders
September 25, 2018 - Where to draw the line on incentives
September 25, 2018 - Solid fuel use linked with increased risk of hospitalization or death from respiratory diseases
September 25, 2018 - ‘Trouble Brewing’ report highlights steps that governments can take to reduce alcohol-related harms
September 25, 2018 - Recurrence risk of VTE appears similar for patients with cancer and those with unprovoked VTE
September 25, 2018 - Global leaders must make bold commitments at first-ever UN tuberculosis summit
September 25, 2018 - Brief sleep intervention works long-term to prevent child obesity
September 25, 2018 - Vaping among kids and teens a growing concern
September 25, 2018 - Public launch of products and application solutions from Porvair Laboratory Division
September 25, 2018 - Harmful H. pylori may play a role in Parkinson’s disease
September 25, 2018 - Researchers develop way to measure different types of fear of falling in patients with Parkinson’s
September 25, 2018 - Fracture causes bone density losses throughout the body
September 25, 2018 - Researchers highlight potential therapy for treating rare, deadly blood-clotting disorder
September 25, 2018 - Hybrid theranostic complex shows high therapeutic efficacy against tumor cells
September 25, 2018 - FDA Issues Statement Reaffirming the Positive Benefit-Risk Profile of Nuplazid (pimavanserin) for Patients with Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis
September 25, 2018 - Toxicological evaluation and dosimetry estimation of potential PET radiotracer
September 25, 2018 - 5 obstacles parents commonly face in child obesity treatment and how to overcome them
September 25, 2018 - Immunologist to study how Chikungunya causes devastating effects in older adults
September 25, 2018 - Rural borderland communities vulnerable to high stress impacting mental and physical health
September 25, 2018 - SNMMI announces recipients of 2018-2020 Wagner-Torizuka Fellowship
September 25, 2018 - Common painkiller not effective in controlling chronic pain after traumatic nerve injury
September 25, 2018 - New therapeutic vaccine helps immune cells fight HPV-related head and neck cancer
September 25, 2018 - Environmentally-induced gene activity influences IQ test performance
September 25, 2018 - Biogen and Eisai announce results of LTE Phase 1b study of aducanumab for treating MCI
September 25, 2018 - FDA Approves Copiktra (duvelisib) Capsules for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma
September 25, 2018 - Medical device company settles US case over false claims
September 25, 2018 - Trying to get answers: One woman’s quest for a diagnosis
September 25, 2018 - Lung cancer patients treated with invasive surgery more likely to become chronic opioid users
September 25, 2018 - Oxford VR raises £3.2m to boost innovation in VR for mental health problems
September 25, 2018 - Gene therapy approach could help treat mitochondrial diseases
September 25, 2018 - Few Yogurt Products Qualify As Low-Sugar
September 25, 2018 - Eye disease can cause blindness, and it’s on the rise
September 25, 2018 - Pawnshop density linked to gun-related suicides, Stanford study finds
September 25, 2018 - Pioneering procedure for common prostate condition offered by The London Clinic
September 25, 2018 - Number of people with respiratory diseases likely to increase if UK air pollution remains unchecked
September 25, 2018 - FARXIGA receives positive results in Phase III DECLARE-TIMI 58 cardiovascular outcomes trial
September 25, 2018 - New program to reduce harmful stress effectively improves mood in cancer patients
September 24, 2018 - Florence’s Lingering Threat: Mold – Drugs.com MedNews
September 24, 2018 - For professional baseball players, faster hand-eye coordination linked to batting performance
September 24, 2018 - Bill for later school start times is defeated, but Stanford sleep specialist isn’t
September 24, 2018 - For Heart Failure Patients, Mitral Valve Procedure Improved Outcomes
September 24, 2018 - Successful recovery from addiction means more than achieving abstinence
September 24, 2018 - New nanoplatform technology may reverse drug-resistance in renal cell carcinoma
September 24, 2018 - October 1918 marks the centenary of Spanish Flu that claimed more lives than World War I
September 24, 2018 - LGBT community reports more number of poor mental health days than general population
September 24, 2018 - New research suggests power of zebrafish as tool for cancer drug discovery
September 24, 2018 - New study finds height as possible risk factor for developing varicose veins
September 24, 2018 - Researchers compare weight loss results of online and in-person diabetes prevention program
September 24, 2018 - New HER2 PET Study Uses Affibody’s ABY-025 Tracer to Individualize Breast Cancer Treatment
CDC recommends new vaccine for shingles

CDC recommends new vaccine for shingles

image_pdfDownload PDFimage_print

Last month a U.S. Food and Drug Administration (FDA) advisory panel had voted 11 to 0 approving a shingles vaccine for its use in adults aged 50 and over. The panel unanimously accepted the safety and efficacy of the vaccine and thus GlaxoSmithKline’s Shingrix.

This new vaccine since then has received the FDA approval this Monday. A federal committee of experts that advises the Centre of Disease Prevention and Control (CDC) yesterday (25th of October 2017), recommends the use of Shingrix for all persons over 50 years of age.

Shingles / herpes zoster. Image Credit: SneSivan / Shutterstock

Shingles / herpes zoster. Image Credit: SneSivan / Shutterstock

The Advisory Committee on Immunization Practices advises the CDC on current practices. The committee said that adults who have already received the earlier approved vaccine Zostavax (a shingles vaccine made by Merck) are to be vaccinated again with this new vaccine Shingrix. Shingrix, the committee said, is to be preferred over Zostavax. Until now the only vaccine against herpes zoster was Zostavax that was approved in 2006 for persons over the age of 60 years.

The committee has found that Zostavax is 51 percent effective in preventing the herpes zoster or shingles and 67 percent effective against postherpetic neuralgia whereas Shingrix is 97 percent effective in preventing shingles between ages 50 and 69 years. Shingrix is 91 percent effective in preventing shingles in those over 70 years. Shingrix can prevent postherpetic neuralgia in 91 percent cases over 50 years. These results have been studied in over 38,000 participants making the results reliable. With time Zostavax loses its efficacy. Within one year of vaccination the efficacy of Zostavax is lost by 15 to 25 percent. Within 9 years the protection is lost. Shingrix till date has been studied for up to four years only and it has been seen that its efficacy remains 85 percent for up to four years post vaccination.

According to Dr. Kathleen Dooling, a medical officer in the CDC’s division of viral disease, the final recommendation is expected to be released early next year. Dr. Dooling said, “The Shingrix vaccine has the potential to prevent tens of thousands of cases of shingles and its complications.”

Shingles and its Vaccines

Shingles or herpes zoster is actually a reactivation of the varicella-zoster virus that had caused a chicken pox infection in the person previously. The varicella zoster virus usually remains dormant in a person’s body and in times of weakened immunity such as in old age or during disease, the virus resurfaces as the painful blisters.

The blisters usually cluster in one place on one side of the body leading to burning, tingling or numbing pain. This gets dry and forms crusts over 2 to 3 weeks. The rash affects one side of the torso or may appear over face, forehead, eyes, mouth, and ears on one side. It typically follows distribution and branches of a nerve. Facial shingles is called Ramsay Hunt Syndrome. Sometimes the nerve pain may persist in 10 to 18 percent individuals. This is called Post herpetic neuralgia. When shingles affects the eyes or ears, it can leave a person blind or deaf. According to the CDC, there are approximately 1 million new cases of shingles each year in the US. 20 million people over the age of 60 have received the Zostavax vaccine.

There are essentially two types of vaccines against viral infections;

  • Live attenuated vaccine wherein weaker version of the virus is introduced in the body with the vaccine dose to teach the body’s immune system to fight the virus. This way when the virus actually is encountered, the body remembers and fights the infection successfully.
  • Subunit vaccine where only a part of the dead virus is introduced into the body. This subunit is an essential part of the virus that the body must recognize. This way too the body learns how to fight the virus when it really encounters it.

Zostavax is a live attenuated vaccine whereas Shingrix is a non-live, subunit vaccine. Because a whole weakened virus is not introduced with the vaccine the risk of getting side effects and adverse events with the vaccine is lower with Shingrix. Zostavax is given as a single shot. For Shingrix the recommended dosage is one shot each given at two months interval.

GSK has assured that the new vaccine would be available on the shelves soon. It is expected to cost about $280. Zostavax costs $223.

Tagged with:

About author

Related Articles